The Osaka High Court has recommended that the parties involved in a lawsuit over hepatitis C virus infections caused by the use of tainted blood products compromise and reach a settlement. It is hoped that the state and drug makers will be ready to take responsibility for the medical disaster and apologize to the plaintiffs so that a court-mediated settlement can be reached. The settlement would serve as a first step toward solving health problems that affect more than 10,000 people.

In and after 2002, a total of 171 people infected with hepatitis C virus through the use of tainted blood products, mainly the hemostatic agent fibrinogen, filed lawsuits for compensation with lower courts in Tokyo, Osaka, Fukuoka, Sendai and Nagoya. By September 2007, four of the five courts ruled that both the state and drug makers bear responsibility for the health damage. Only the Sendai court decided that the drug makers alone have responsibility.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.